Engineered Extracellular Vesicles for Stronger T Cell Vaccine Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing extracellular vesicles (EVs), such as exosomes, have limited clinical efficacy as drug delivery vehicles and immunotherapy agents, particularly in treating conditions like non-small cell lung cancer, due to insufficient immune response induction and interaction with T cells.
Innovation Solution
Engineered EVs are developed with antigens and adjuvants, anchored or linked to scaffold moieties on the surface or within the lumen, to enhance immune response induction, specifically targeting dendritic cells and T cells, using scaffold proteins like PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, ATP transporters, MARCKS, and BASP1, and immune modulators like CTLA-4 inhibitors and co-stimulatory molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional EVs (e.g., dendritic-cell derived exosomes) are used as immunotherapy agents, then they can be administered to patients, but they fail to induce sufficient immune response and show limited clinical efficacy
Solution Approach 1:
The patent combines multiple functional components into a single engineered EV system: antigens are incorporated to provide tumor-specific targeting, adjuvants are included to stimulate immune activation, and these components are integrated within the EV structure to work synergistically. This merging of components resolves the contradiction by creating a system that both targets cancer cells and induces sufficient immune response simultaneously
Solution Approach 2:
The engineered EVs represent composite biological materials combining lipid bilayer membranes with embedded proteins, antigens, and adjuvants. This composite structure allows the EV to function both as a delivery vehicle and as an immune stimulator, resolving the contradiction between administerability and clinical efficacy by integrating multiple functions into one composite system
2Reliability
If EVs are designed to interact with T cells to enhance immune response, then immune response induction improves, but the mechanism becomes more complex requiring direct TCR interaction
Solution Approach 1:
The patent uses engineered EVs as intermediary carriers that bridge the gap between antigen presentation and T cell activation. Instead of requiring direct complex TCR interactions, the EV acts as a mediator that presents antigens and delivers adjuvants to immune cells, simplifying the interaction mechanism while maintaining effective immune response induction
Solution Approach 2:
The engineered EVs perform multiple functions simultaneously: they serve as antigen carriers, adjuvant delivery vehicles, and immune cell targeting agents. This multi-functionality resolves the contradiction by providing a universal platform that induces immune responses through multiple pathways rather than relying on a single complex TCR interaction mechanism
Data Source
AI summary
The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and/or immune modulator) and/or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and/or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.